Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Giles

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Lancet (London, England)|July 9, 1988
Alpha-interferon therapy for essential thrombocythaemiaF J Giles, C R Singer, A G Gray, et al.
British Journal of Cancer|October 22, 2011
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinomaD Mahalingam, C M Espitia, E C Medina, et al.
British Journal of Cancer|September 21, 2013
The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistanceA P Toner, F McLaughlin, F J Giles, et al.
British Journal of Haematology|September 1, 1993
Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemiaE N McSweeney, F J Giles, C P Worman, et al.
Hematology (Amsterdam, Netherlands)|July 14, 2016
Skin Necrosis Associated With Heparin-Induced Thrombocytopenia and ThrombosisF J Giles, T J Kanemaki, J T Otsuki, et al.
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
Leukemia & Lymphoma|November 9, 2001
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndromeB S Dabaja, S M O'Brien, H M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabineH M Kantarjian, S O'Brien, T L Smith, et al.
Leukemia|September 16, 2015
Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinibK Wenn, L Tomala, S Wilop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S O'Brien, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Lancet (London, England)|July 9, 1988
Alpha-interferon therapy for essential thrombocythaemiaF J Giles, C R Singer, A G Gray, et al.
British Journal of Cancer|October 22, 2011
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinomaD Mahalingam, C M Espitia, E C Medina, et al.
British Journal of Cancer|September 21, 2013
The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistanceA P Toner, F McLaughlin, F J Giles, et al.
British Journal of Haematology|September 1, 1993
Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemiaE N McSweeney, F J Giles, C P Worman, et al.
Hematology (Amsterdam, Netherlands)|July 14, 2016
Skin Necrosis Associated With Heparin-Induced Thrombocytopenia and ThrombosisF J Giles, T J Kanemaki, J T Otsuki, et al.
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
Leukemia & Lymphoma|November 9, 2001
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndromeB S Dabaja, S M O'Brien, H M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabineH M Kantarjian, S O'Brien, T L Smith, et al.
Leukemia|September 16, 2015
Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinibK Wenn, L Tomala, S Wilop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S O'Brien, et al.
Pageof 13